The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for IRRIMAX sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
IRRIMAX , a subsidiary of Innovation Technologies Inc develops, manufactures, and distributes products to prevent wound-related infections. The company’s major product, Irrisept antimicrobial wound lavage, is a single-use, manual, self-contained irrigation device that contains low-concentration Chlorhexidine Gluconate in sterile water for irrigation. The product acts as a preservative to help inhibit microbial growth in the solution. The company offers its products through distributors including AmerisourceBergen; Cardinal; Claflin; Concordance; Henry Schein; McKesson; Medline; Owens & Minor; and RIMACO. IRRIMAX is headquartered in Lawrenceville, Georgia, the US.
The key metrics of IRRIMAX related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As IRRIMAX is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as IRRIMAX.
For a detailed understanding of the performance of IRRIMAX, buy the report here.